Trial of Anifrolumab in Active Systemic Lupus ErythematosusEric F. Morand, Raj Tummala, Anca Askanase et al.|New England Journal of Medicine|2019Cited by 1.3k
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trialRichard Furie, Raj Tummala, Eric F. Morand et al.|The Lancet Rheumatology|2019Cited by 478